- A commitment to go personally after Pharma execs who violate the law around marketing off label drugs, rather than just slap the company with a fine. A former Glaxo lawyer has been indicted for lying to the FDA in such a case.
- Doing away with the Bush administration practice of demanding that warning letters sent to companies first have to go through a review by the Legal department--which turned out to massively slow down the process of issuing such letters.
- Increasing foreign inspections in the wake of scandals regarding unsafe imported chemicals, and making moves to hold US companies responsible for shoddy imported ingredients.
Some say it's about time.